avastin

Generic: bevacizumab

Labeler: genentech, inc.
NDC Directory HUMAN PRESCRIPTION DRUG BLA Inactive Finished

Drug Facts

Product Profile

Brand Name avastin
Generic Name bevacizumab
Labeler genentech, inc.
Dosage Form INJECTION, SOLUTION
Routes
INTRAVENOUS
Active Ingredients

bevacizumab 400 mg/16mL

Manufacturer
Genentech, Inc.

Identifiers & Regulatory

Product NDC 50242-061
Product ID 50242-061_8debebf6-af94-4ba7-8d67-c801f4ea27eb
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category BLA
Application Number BLA125085
Listing Expiration 2026-12-31
Marketing Start 2004-02-26

Pharmacologic Class

Established (EPC)
vascular endothelial growth factor inhibitor [epc]
Mechanism of Action
vascular endothelial growth factor-directed antibody interactions [moa] vascular endothelial growth factor inhibitors [moa]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 50242061
Hyphenated Format 50242-061

Supplemental Identifiers

RxCUI
1657066 1657068 1657073 1657074
UNII
2S9ZZM9Q9V
NUI
N0000193543 N0000178291 N0000193542

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name avastin (source: ndc)
Generic Name bevacizumab (source: ndc)
Application Number BLA125085 (source: ndc)
Routes
INTRAVENOUS
source: ndc

Resolved Composition

Strengths
  • 400 mg/16mL
source: ndc
Packaging
  • 1 VIAL, SINGLE-USE in 1 CARTON (50242-061-01) / 16 mL in 1 VIAL, SINGLE-USE
source: ndc

Packages (1)

Ingredients (1)

bevacizumab (400 mg/16mL)

Linked Drug Pages (1)

Raw FDA Data

View complete raw FDA NDC JSON payload
{"route": ["INTRAVENOUS"], "spl_id": "8debebf6-af94-4ba7-8d67-c801f4ea27eb", "openfda": {"nui": ["N0000193543", "N0000178291", "N0000193542"], "unii": ["2S9ZZM9Q9V"], "rxcui": ["1657066", "1657068", "1657073", "1657074"], "spl_set_id": ["939b5d1f-9fb2-4499-80ef-0607aa6b114e"], "pharm_class_epc": ["Vascular Endothelial Growth Factor Inhibitor [EPC]"], "pharm_class_moa": ["Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]", "Vascular Endothelial Growth Factor Inhibitors [MoA]"], "manufacturer_name": ["Genentech, Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 VIAL, SINGLE-USE in 1 CARTON (50242-061-01)  / 16 mL in 1 VIAL, SINGLE-USE", "package_ndc": "50242-061-01", "marketing_start_date": "20040226"}], "brand_name": "Avastin", "product_id": "50242-061_8debebf6-af94-4ba7-8d67-c801f4ea27eb", "dosage_form": "INJECTION, SOLUTION", "pharm_class": ["Vascular Endothelial Growth Factor Inhibitor [EPC]", "Vascular Endothelial Growth Factor Inhibitors [MoA]", "Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]"], "product_ndc": "50242-061", "generic_name": "bevacizumab", "labeler_name": "Genentech, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Avastin", "active_ingredients": [{"name": "BEVACIZUMAB", "strength": "400 mg/16mL"}], "application_number": "BLA125085", "marketing_category": "BLA", "marketing_start_date": "20040226", "listing_expiration_date": "20261231"}